text
"['\n1. 요약재무정보\n당사는 2018년 9월 19일 발표된 [제약ㆍ바이오 기업의 연구개발비 회계처리 관련 감독지침]을 고려, 개발비 자산화 시점의 회계처리 오류(무형자산 과대계상 및 경상연구개발비 과소계상 등)를 수정하였으며, 이에 따라 제27기(전기) 및 제26기(전전기) 재무재표는 소급 재작성되었습니다. \n가. 요약연결재무정보\n(단위: 원)\n구 분\n제28기\n제27기\n제26기\n(2018년 12월말)\n(2017년 12월말)\n(2016년 12월말)\n[유동자산]\n1,664,281,326,370\xa0\n1,614,033,788,024\xa0\n1,240,249,662,127\xa0\n\xa0ㆍ현금및현금성자산\n410,547,608,852\xa0\n419,205,662,651\xa0\n268,408,116,475\xa0\n\xa0ㆍ단기금융자산\n121,636,304,845\xa0\n138,717,014,000\xa0\n5,765,335,000\xa0\n\xa0ㆍ매출채권\n807,711,314,915\xa0\n828,394,032,126 \xa0\n758,305,090,542\xa0\n\xa0ㆍ기타수취채권\n124,267,624,254\xa0\n3,211,880,582\xa0\n4,830,010,171\xa0\n\xa0ㆍ재고자산\n162,916,820,624\xa0\n199,481,840,555\xa0\n170,938,986,135\xa0\n\xa0ㆍ당기법인세자산\n9,523,563,778\xa0\n9,780,837,220\xa0\n9,903,568,960\xa0\n\xa0ㆍ기타유동자산\n27,678,089,102\xa0\n15,242,520,890\xa0\n22,098,554,844\xa0\n[비유동자산]\n1,838,826,878,560\xa0\n1,680,062,197,809\xa0\n1,643,597,744,102\xa0\n\xa0ㆍ장기금융자산\n18,989,084,041\xa0\n15,686,919,883\xa0\n15,342,266,303\xa0\n\xa0ㆍ장기매출채권\n0\xa0\n0\xa0\n517,859,475\xa0\n\xa0ㆍ장기기타수취채권\n10,287,886,409\xa0\n8,562,470,441\xa0\n8,502,191,390\xa0\n\xa0ㆍ관계기업투자\n28,003,078,925\xa0\n17,006,445,302\xa0\n6,157,106,430\xa0\n\xa0ㆍ유형자산\n881,437,749,875\xa0\n844,212,382,151\xa0\n867,921,681,510\xa0\n\xa0ㆍ무형자산\n885,018,659,777\xa0\n788,358,689,859\xa0\n720,181,970,037\xa0\n\xa0ㆍ이연법인세자산\n0\xa0\n0\xa0\n20,640,513,438\xa0\n\xa0ㆍ기타비유동자산\n15,090,419,533\xa0\n6,235,290,173\xa0\n4,334,155,519\xa0\n자산총계\n3,503,108,204,930\xa0\n3,294,095,985,833\xa0\n2,883,847,406,229\xa0\n[유동부채]\n678,087,471,395\xa0\n616,781,029,714\xa0\n610,253,362,180\xa0\n[비유동부채]\n229,761,340,951\xa0\n266,817,280,825\xa0\n212,720,844,392\xa0\n부채총계\n907,848,812,346\xa0\n883,598,310,539\xa0\n822,974,206,572\xa0\n[자본금]\n125,456,133,000\xa0\n122,666,424,000\xa0\n116,598,327,000\xa0\n[주식발행초과금]\n761,047,500,208\xa0\n741,748,885,673\xa0\n729,423,471,164\xa0\n[이익잉여금]\n1,665,189,222,641\xa0\n1,429,153,613,949\xa0\n1,066,759,835,822\xa0\n[기타포괄손익누계액]\n9,970,124,880\xa0\n8,720,587,567\xa0\n6,513,014,001\xa0\n[기타자본항목]\n(75,159,128,990)\xa0\n(14,828,853,103)\xa0\n28,283,249,859\xa0\n[비지배지분]\n108,755,540,845\xa0\n123,037,017,208\xa0\n113,295,301,811\xa0\n자본총계\n2,595,259,392,584\xa0\n2,410,497,675,294\xa0\n2,060,873,199,657\xa0\n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n(2016.01.01~2016.1.31)\n매출액\n982,074,959,799\xa0\n949,079,965,214\xa0\n670,580,961,669\xa0\n영업이익\n323,131,558,365\xa0\n499,585,550,587\xa0\n221,243,034,062\xa0\n법인세비용차감전순이익\n301,639,078,511\xa0\n483,071,479,107\xa0\n197,433,293,219\xa0\n당기순이익\n237,476,360,558\xa0\n377,725,080,593\xa0\n149,418,660,913\xa0\n\xa0ㆍ지배기업소유주지분\n245,755,018,366\xa0\n368,221,994,127\xa0\n158,957,521,808\xa0\n\xa0ㆍ비지배지분\n(8,278,657,808)\xa0\n9,503,086,466\xa0\n(9,538,860,895)\xa0\n\xa0ㆍ기본주당이익\n1,971\xa0\n2,956\xa0\n1,279\xa0\n연결에 포함된 회사수\n8\n6\n7\n나. 요약재무정보\n(단위: 원)\n구 분\n제28기\n제27기\n제26기\n(2018년 12월말)\n(2017년 12월말)\n(2016년 12월말)\n[유동자산]\n1,482,310,007,849\xa0\n1,421,211,524,496\xa0\n1,076,603,083,554\xa0\n\xa0ㆍ현금및현금성자산\n399,558,425,745\xa0\n413,501,866,488\xa0\n257,604,838,606\xa0\n\xa0ㆍ단기금융자산\n121,636,304,845\xa0\n138,402,014,000\xa0\n5,450,335,000\xa0\n\xa0ㆍ매출채권\n689,472,264,429\xa0\n713,489,012,682\xa0\n678,463,204,095\xa0\n\xa0ㆍ기타수취채권\n123,885,214,981\xa0\n3,133,116,830\xa0\n3,864,647,697\xa0\n\xa0ㆍ재고자산\n125,717,441,514\xa0\n141,164,307,648\xa0\n113,118,543,355\xa0\n\xa0ㆍ기타유동자산\n22,040,356,335\xa0\n11,521,206,848\xa0\n18,101,514,801\xa0\n[비유동자산]\n1,888,329,253,915\xa0\n1,716,972,980,244\xa0\n1,646,143,636,158\xa0\n\xa0ㆍ장기금융자산\n17,407,490,899\xa0\n14,354,326,741\xa0\n14,009,673,161\xa0\n\xa0ㆍ장기기타수취채권\n9,141,484,165\xa0\n7,169,744,638\xa0\n7,053,707,465\xa0\n\xa0ㆍ종속기업및관계기업투자\n286,212,166,532\xa0\n273,099,081,283\xa0\n262,117,281,283\xa0\n\xa0ㆍ유형자산\n677,870,722,592\xa0\n635,989,041,524\xa0\n649,440,392,764\xa0\n\xa0ㆍ무형자산\n877,141,249,708\xa0\n774,478,435,302\xa0\n703,792,726,623\xa0\n\xa0ㆍ투자부동산\n5,982,493,446\xa0\n6,147,170,166\xa0\n6,336,536,303\xa0\n\xa0ㆍ기타비유동자산\n14,573,646,573\xa0\n5,735,180,590\xa0\n3,393,318,559\xa0\n자산총계\n3,370,639,261,764\xa0\n3,138,184,504,740\xa0\n2,722,746,719,712\xa0\n[유동부채]\n548,121,290,075\xa0\n491,067,961,229\xa0\n524,271,608,642\xa0\n[비유동부채]\n218,455,704,094\xa0\n242,174,301,750\xa0\n125,584,949,957\xa0\n부채총계\n766,576,994,169\xa0\n733,242,262,979\xa0\n649,856,558,599\xa0\n[자본금]\n125,456,133,000\xa0\n122,666,424,000\xa0\n116,598,327,000\xa0\n[주식발행초과금]\n761,047,500,208\xa0\n741,748,885,673\xa0\n729,423,471,164\xa0\n[이익잉여금]\n1,793,330,987,094\xa0\n1,556,788,491,161\xa0\n1,200,532,713,975\xa0\n[기타포괄손익누계액]\n5,011,173,208\xa0\n4,512,733,369\xa0\n3,024,273,130\xa0\n[기타자본항목]\n(80,783,525,915)\xa0\n(20,774,292,442)\xa0\n23,311,375,844\xa0\n자본총계\n2,604,062,267,595\xa0\n2,404,942,241,761\xa0\n2,072,890,161,113\xa0\n종속ㆍ관계ㆍ공동기업투자주식의 평가방법\n원가법\n원가법\n원가법\n(2018.01.01~2018.12.31)\n(2017.01.01~2017.1.31)\n(2016.01.01~2016.1.31)\n매출액\n861,884,226,306\xa0\n828,917,201,749\xa0\n577,574,961,774\xa0\n영업이익\n319,413,201,208\xa0\n477,891,619,440\xa0\n246,217,340,210\xa0\n법인세비용차감전순이익\n296,187,867,991\xa0\n468,527,542,691\xa0\n261,444,895,791\xa0\n당기순이익\n238,274,199,791\xa0\n362,083,993,186\xa0\n213,235,760,729\xa0\n\xa0ㆍ기본주당이익\n1,911\xa0\n2,907\xa0\n1,716\xa0\n']"
